Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Dull AB"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
El Touny LH; Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA.; Current address: Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, MD, USA., Hose C; Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA., Connelly J; Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA., Harris E; Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA., Monks A; Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA., Dull AB; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA., Wilsker DF; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA., Hollingshead MG; Biological Testing Branch, NCI, Frederick, MD, USA., Gottholm-Ahalt M; Biological Testing Branch, NCI, Frederick, MD, USA., Alcoser SY; Biological Testing Branch, NCI, Frederick, MD, USA., Mullendore ME; In Vivo Evaluation Program, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA., Parchment RE; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, MD, USA.; Developmental Therapeutics Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, MD, USA., Teicher BA; Developmental Therapeutics Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, MD, USA.; Molecular Pharmacology Branch, Developmental Therapeutics Program, NCI, Rockville, MD, USA., Rapisarda A; Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA.
Publikováno v:
Oncotarget [Oncotarget] 2021 Oct 12; Vol. 12 (21), pp. 2114-2130. Date of Electronic Publication: 2021 Oct 12 (Print Publication: 2021).
Autor:
Hernandez LF; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Dull AB; Clinical Pharmacodynamics Program, Frederick National Laboratory/Leidos, Frederick, MD, USA., Korrapati S; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Annunziata CM; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. annunzic@mail.nih.gov.
Publikováno v:
Cell death discovery [Cell Death Discov] 2021 Jun 04; Vol. 7 (1), pp. 134. Date of Electronic Publication: 2021 Jun 04.
Autor:
Coyne GO; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Kummar S; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Current address: Knight Cancer Institute, Oregon Health Sciences University, Portland, OR, USA., Meehan RS; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Do K; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Collins JM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA., Anderson L; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA., Ishii K; Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Takebe N; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zlott J; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Juwara L; Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Piekarz R; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Streicher H; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Sharon E; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Rubinstein L; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Voth AR; Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Lozier J; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Dull AB; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Wilsker D; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Hinoue T; Van Andel Institute, Center for Epigenetics, Grand Rapids, MI, USA., Laird PW; Van Andel Institute, Center for Epigenetics, Grand Rapids, MI, USA., Ferry-Galow KV; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Kinders RJ; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Parchment RE; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, and Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Chen AP; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Publikováno v:
Oncotarget [Oncotarget] 2020 Nov 03; Vol. 11 (44), pp. 3959-3971. Date of Electronic Publication: 2020 Nov 03 (Print Publication: 2020).
Autor:
Wilsker DF; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland. kindersr@mail.nih.gov deborah.wilsker@nih.gov., Barrett AM; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland., Dull AB; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland., Lawrence SM; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland., Hollingshead MG; Biological Testing Branch, NCI, Frederick, Maryland., Chen A; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Kummar S; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Parchment RE; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.; Developmental Therapeutics Branch, Center for Cancer Research, NCI, Bethesda, Maryland., Kinders RJ; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland. kindersr@mail.nih.gov deborah.wilsker@nih.gov.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 May 15; Vol. 25 (10), pp. 3084-3095. Date of Electronic Publication: 2019 Feb 21.
Autor:
Dull AB; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Wilsker D; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Hollingshead M; Biological Testing Branch, National Cancer Institute-Frederick, Frederick, Maryland, USA., Mazcko C; Comparative Oncology Program, National Cancer Institute, Bethesda, Maryland, USA., Annunziata CM; Women's Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA., LeBlanc AK; Comparative Oncology Program, National Cancer Institute, Bethesda, Maryland, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Kinders RJ; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Parchment RE; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Publikováno v:
Oncotarget [Oncotarget] 2018 Mar 30; Vol. 9 (24), pp. 17104-17116. Date of Electronic Publication: 2018 Mar 30 (Print Publication: 2018).
Autor:
Dull AB; 1SAIC-Frederick, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., George AA, Goncharova EI, Evans JR, Wamiru A, Cartner LK, Hager GL, McMahon JB
Publikováno v:
Journal of biomolecular screening [J Biomol Screen] 2014 Feb; Vol. 19 (2), pp. 242-52. Date of Electronic Publication: 2013 Sep 19.
Autor:
Best AM; Department of Pharmacology and Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390, USA., Chang J, Dull AB, Beutler JA, Martinez ED
Publikováno v:
Journal of biomedicine & biotechnology [J Biomed Biotechnol] 2011; Vol. 2011, pp. 868095. Date of Electronic Publication: 2010 Dec 22.
Autor:
Martinez ED; Laboratory of Receptor Biology and Gene Expression, Hormone Action and Oncogenesis Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA., Dull AB, Beutler JA, Hager GL
Publikováno v:
Methods in enzymology [Methods Enzymol] 2006; Vol. 414, pp. 21-36.